Publication:
Prognostic Implications of the Timing of ST-Elevation Myocardial Infarction Development in Relation to COVID-19 Infection

dc.contributor.authorMilošević, Aleksandra D. (56622640900)
dc.contributor.authorPolovina, Marija M. (35273422300)
dc.contributor.authorJelic, Dario D. (57201640680)
dc.contributor.authorSimic, Damjan D. (58010380500)
dc.contributor.authorViduljevic, Mihajlo M. (57266248400)
dc.contributor.authorMatic, Dragan M. (25959220100)
dc.contributor.authorTomic, Milenko M. (58629586600)
dc.contributor.authorAdzic, Tatjana N. (23099138200)
dc.contributor.authorAsanin, Milika R. (8603366900)
dc.date.accessioned2025-06-12T11:41:49Z
dc.date.available2025-06-12T11:41:49Z
dc.date.issued2024
dc.description.abstractBackground: Patients with ST-segment elevation myocardial infarction (STEMI) and COVID-19 infection have a worse clinical course and prognosis. The prognostic significance of the timing of STEMI in relation to COVID-19 infection was not investigated. Objectives: To assess whether the time of STEMI development in relation to COVID-19 infection (concurrent or following the infection) influenced the short-term prognosis. Methods: This was an observational study of consecutive COVID-19 patients with STEMI admitted to the COVID-hospital Batajnica (February 2021–March 2022). The patients were divided into the “STEMI first” group: patients with STEMI and a positive polymerase chain reaction test for COVID-19, and the “COVID-19 first” group: patients who developed STEMI during COVID-19 treatment. All patients underwent coronary angiography. The primary endpoint was in-hospital all-cause mortality. Results: The study included 87 patients with STEMI and COVID-19 (Mage, 66.7 years, 66% male). The “STEMI first” group comprised 54 (62.1%) patients, and the “COVID-19 first” group included 33 (37.9%) patients. Both groups shared a comparatively high burden of comorbidities, similar angiographic and procedural characteristics, and high percentages of performed percutaneous coronary interventions with stent implantation (90.7% vs. 87.9%). In-hospital mortality was significantly higher in the “COVID-19 first” group compared to the “STEMI first” group (51.5% vs. 27.8%). Following adjustment, the “COVID-19 first” group had a hazard ratio of 3.22 (95% confidence interval, 1.18–8.75, p =.022) for in-hospital all-cause death, compared with the “STEMI first” group (reference). Conclusion: Clinical presentation with COVID-19 infection, followed by STEMI (“COVID-19 first”), was associated with greater short-term mortality compared to patients presenting with STEMI and testing positive for COVID-19 (“STEMI first”). © The Author(s) 2024.
dc.identifier.urihttps://doi.org/10.1177/08850666241232938
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85186262861&doi=10.1177%2f08850666241232938&partnerID=40&md5=4fb8797b4d8dec6577c1f319dd2f373e
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/992
dc.subjectall-cause mortality
dc.subjectCOVID-19
dc.subjectoutcome
dc.subjectprimary percutaneous coronary intervention
dc.subjectprognosis
dc.subjectST-segment elevation myocardial infarction
dc.titlePrognostic Implications of the Timing of ST-Elevation Myocardial Infarction Development in Relation to COVID-19 Infection
dspace.entity.typePublication

Files